Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis

Neurologia Medico-Chirurgica

Volumn 47, Issue 5, 2007, Pages 203-208

  Tsuiki, Hiromasa ^a,b   Nishi, Toru ^b   Takeshima, Hideo ^a   Yano, Shigetoshi ^a   Nakamura, Hideo ^a   Makino, Keishi ^a   Kuratsu, Jun Ichi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

Author keywords

Glioma; Murin double minute 2; Single nucleotide polymorphism

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER PATIENT; CARCINOGENESIS; CHILD; CONTROLLED STUDY; EPENDYMOMA; FEMALE; GENE MUTATION; GENOTYPE; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OLIGODENDROGLIOMA; ONSET AGE; POPULATION GENETICS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN HEMISPHERE;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, P53; GLIOMA; HUMANS; INFANT; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 34249717285     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.47.203     Document Type: Article

References (17)

1. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA: The MDM2 promoter polymorphism SNP309T->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42: 694-698, 2005
2. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J: A chromatin associated and transcriptionally inactive p53-MDM2 complex occurs in MDM2 SNP 309 homozygous cells. J Biol Chem 280: 26776-26787, 2005
3. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004
4. Campbell IG, Eccles DM, Choong DY: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240: 195-197, 2006
5. Carnevale A, Lieberman E, Cardenas R: Li-Fraumeni syndrome in pediatric patients with soft tissue sarcoma or osteosarcoma. Arch Med Res 28: 383-386, 1997
6. Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H: Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 118: 1275-1278, 2006
7. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Jin G, Liu J, Wei Q, Shen H: Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240: 261-267, 2006
8. Michael D, Oren M: The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12: 53-59, 2002
9. Nakanishi H, Tomita Y, Yoshikawa H, Sato N, Ochi T, Aozasa K: Frequent p53 gene mutations in soft tissue sarcomas arising in burn scar. Jpn J Cancer Res 90: 276-279, 1999
10. Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 109: 93-108, 2005
11. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M: Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol 49: 197-203, 2000
12. Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, Kuratsu J, Ushio Y: Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95: 249-257, 2002
13. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001
14. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, de la Chapelle A: p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 11: 6840-6844, 2005
15. Ushio Y, Tada K, Shiraishi S, Kamiryo T, Shinojima N, Kochi M, Saya H: Correlation ofmolecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci 8: 281-288, 2003
16. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000
17. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 523-530, 1997